Welcome to our dedicated page for Imunon news (Ticker: IMNN), a resource for investors and traders seeking the latest updates and insights on Imunon stock.
Imunon, Inc. (symbol: IMNN) is a biopharmaceutical company focused on the research and development of targeted therapies to address unmet medical needs in oncology. With the recent acquisition of EGEN, Inc., Imunon has transformed into a fully integrated company boasting a comprehensive, multi-phase clinical pipeline. The company specializes in nucleic acid-based immunotherapies and other anti-cancer DNA/RNA therapies. Their platform technologies are designed to leverage the body's natural mechanisms, aiming to generate safe, effective, and durable responses across a wide range of human diseases.
Imunon is committed to innovation and excellence in the field of biotechnology, seamlessly integrating research from the laboratory to clinical applications. By harnessing the building blocks of life, the company strives to work in harmony with the body's immune system to develop groundbreaking treatments.
The company's current projects include a variety of clinical trials that seek to validate the efficacy and safety of their therapies. These efforts are supported by a team of experts with extensive experience in drug development. Imunon's financial health is robust, enabling continuous research and the potential for future growth. Additionally, the company values strategic partnerships that bolster its capabilities and extend its reach in the biotech industry.
For investors and stakeholders, Imunon, Inc. represents a promising opportunity in the field of biopharmaceuticals, with a strong focus on innovative cancer treatments and a commitment to addressing significant healthcare challenges.
IMUNON, a clinical-stage biotechnology company, presented promising preclinical data for its PLACCINE platform at the Vaccine Technology Summit 2023. The data indicates robust immunogenicity and protection in SARS-CoV-2 models, with durable cellular responses lasting over 12 months. Notably, compared to a commercial mRNA vaccine, the PLACCINE demonstrated superior immune quality in single-dose tests and comparable protection in booster-dose assessments. The platform offers advantages such as a shelf-life exceeding nine months at 4°C and efficient manufacturing capabilities. IMUNON is advancing its innovative DNA-mediated immunotherapy and next-gen vaccines to combat various diseases.
Imunon, Inc. (NASDAQ: IMNN) announced the approval of equity awards as inducements for two new employees. The Compensation Committee granted stock options to purchase 5,250 shares at an exercise price of $1.32, equal to the closing price on March 17, 2023. These options will vest over four years, starting after one year of employment. Additionally, 1,100 shares of restricted stock were granted, vesting after one year. Imunon is advancing DNA-based immunotherapy and vaccines, with its lead program IMNN-001 in Phase 2 development for advanced ovarian cancer.
IMUNON (NASDAQ: IMNN) announced the acceptance of an abstract on its DNA-based immunotherapy, IMNN-001, for presentation at the AACR Annual Meeting from April 14-19, 2023. The abstract, titled "Efficacy of GEN-1, an interleukin-12 immune gene therapy, at different dose frequencies," will be presented on April 18, 2023, from 9:00 AM to 12:30 PM at the Orange County Convention Center in Orlando, FL. The company continues to advance its clinical-stage immunotherapy for advanced ovarian cancer, seeking to harness the body's immune response to improve treatment outcomes.
IMUNON (NASDAQ: IMNN) recently shared key achievements from 2022 and outlined strategic objectives for 2023. Dr. Corinne Le Goff, CEO, highlighted a transformative shift, including the company’s rebranding and an innovative focus on DNA-based immunotherapies and vaccines. The company raised over $60 million from common stock sales, ending Q3 2022 with $43.4 million in cash and investments. Significant milestones include the enrollment of 110 patients in the OVATION 2 Study for the IL-12 gene therapy, IMNN-001, and advancements in the PLACCINE vaccine technology, showing promising results in animal studies. They anticipate filing an IND application for a COVID-19 booster vaccine in 2023.
IMUNON (NASDAQ: IMNN) announces the start of patient enrollment in a collaboration with Break Through Cancer to evaluate IMNN-001 in combination with bevacizumab for advanced ovarian cancer. This Phase 1/2 trial at MD Anderson aims to enroll 50 patients, focusing on minimal residual disease detection and progression-free survival. Initial results are expected within a year, with final data anticipated in three years. IMUNON will invest $2.0-$2.5 million towards the trial, which aims to enhance treatment outcomes for Stage III/IV ovarian cancer patients, characterized by low cure rates.
IMUNON, Inc. (NASDAQ: IMNN) has secured $1.6 million from the sale of unused New Jersey net operating losses (NOLs) through the NJEDA's Technology Business Tax Certificate Transfer program. This funding strengthens its balance sheet and extends its operational runway into 2025. The company plans to sell an additional $1.8 million in NOLs in 2023. In the past five years, IMUNON has generated over $18 million from NOL sales, enhancing its capacity for research and development amid challenging capital markets.
IMUNON (NASDAQ: IMNN) has signed a collaborative research agreement with The Wistar Institute to develop new vaccine formulations using IMUNON’s PLACCINE modality. This partnership aims to expand vaccine targets and optimize product quality. Dr. Corinne Le Goff, CEO of IMUNON, expressed enthusiasm for working with Wistar's expertise in immunology and infectious diseases. IMUNON is focused on advancing nucleic acid-based therapies, including its lead program, GEN-1, currently in Phase II for advanced ovarian cancer. The company is also validating its PLACCINE platform for a vaccine candidate against SARS-CoV-2.
IMUNON, Inc. (NASDAQ: IMNN) announced the grant of stock options and restricted stock totaling 23,000 shares to incentivize four new employees. The inducement options allow for the purchase of 19,000 shares at an exercise price of $1.40, the closing price on December 13, 2022. These options will vest over three years, while the restricted stock vests after one year. IMUNON focuses on DNA-based immunotherapy and vaccines, with its lead program, GEN-1, in Phase II for advanced ovarian cancer treatment. The company aims to leverage its technological platforms for innovative treatments across various diseases.
IMUNON, Inc. (NASDAQ: IMNN) presented its innovative PLACCINE vaccine modality at the World Vaccine & Immunotherapy Congress in San Diego. The presentation highlighted proof-of-concept data demonstrating immunogenic responses and durable viral clearance from SARS-CoV-2 in animal models. IMUNON's non-viral, plasmid DNA vaccine showed effective results and stability for up to six months. The PLACCINE platform offers advantages such as a durable immune response, safe delivery, and flexible manufacturing, aiming to revolutionize vaccine development.
IMUNON (NASDAQ: IMNN) announced participation in A.G.P.’s Biotech Conference from November 30 to December 1, 2022. Dr. Corinne Le Goff and Mr. Jeffrey Church will represent the company in one-on-one virtual investor meetings. Investors interested in meeting with IMUNON management can contact their A.G.P. representative. The company's lead program, GEN-1, is an innovative DNA-based immunotherapy targeting advanced ovarian cancer, currently in Phase II trials. More details can be found in IMUNON's corporate presentation linked in the announcement.
FAQ
What is the current stock price of Imunon (IMNN)?
What is the market cap of Imunon (IMNN)?
What does Imunon, Inc. specialize in?
What recent acquisition has Imunon, Inc. made?
What is the company's mission?
How does Imunon, Inc. contribute to oncology treatment?
Who are the key players in Imunon, Inc.'s team?
What are the current projects Imunon, Inc. is working on?
How does Imunon, Inc. ensure its financial health?
What makes Imunon, Inc. a good investment opportunity?
How does Imunon, Inc. leverage platform technologies?
What is the significance of Imunon, Inc.'s research and development?
